New insights into tubulin binders

Abstract

Tubulin-binding agents have traditionally been divided into compounds that promote tubulin polymerization (microtubule-stabilizing agents exemplified by the prototypic taxane paclitaxel and docetaxel) and those that promote tubulin depolymerization, including the vinca alkaloids (vincristine, vinblastine and vinorelbine). Only the taxanes have significant activity in the treatment of epithelial ovarian cancer either as single-agent therapy or in combination with platinum agents (Muggia et al. (2000), Covens et al. (2002), International Collaborative Ovarian Neoplasm Group (2002), Parmar et al. (2003), Kyrgiou et al. (2006)). However, despite their utility, taxanes have important clinical limitations, particularly related to drug resistance and adverse effects. This review will focus on the current understanding of how the biology of the microtubule and control of cell cycle may explain taxane resistance and inform the development of new therapeutics and treatment strategies. © 2011 Springer Science+Business Media, LLC.